217 related articles for article (PubMed ID: 15231869)
21. Dual G1 and G2/M phase inhibition by SC-alpha alpha delta 9, a combinatorially derived Cdc25 phosphatase inhibitor.
Tamura K; Rice RL; Wipf P; Lazo JS
Oncogene; 1999 Nov; 18(50):6989-96. PubMed ID: 10597298
[TBL] [Abstract][Full Text] [Related]
22. 2-Methoxyestradiol inhibits hepatocellular carcinoma cell growth by inhibiting Cdc25 and inducing cell cycle arrest and apoptosis.
Kar S; Wang M; Carr BI
Cancer Chemother Pharmacol; 2008 Oct; 62(5):831-40. PubMed ID: 18246350
[TBL] [Abstract][Full Text] [Related]
23. A targeted library of small-molecule, tyrosine, and dual-specificity phosphatase inhibitors derived from a rational core design and random side chain variation.
Rice RL; Rusnak JM; Yokokawa F; Yokokawa S; Messner DJ; Boynton AL; Wipf P; Lazo JS
Biochemistry; 1997 Dec; 36(50):15965-74. PubMed ID: 9398331
[TBL] [Abstract][Full Text] [Related]
24. Identification of new Cdc25 dual specificity phosphatase inhibitors in a targeted small molecule array.
Ducruet AP; Rice RL; Tamura K; Yokokawa F; Yokokawa S; Wipf P; Lazo JS
Bioorg Med Chem; 2000 Jun; 8(6):1451-66. PubMed ID: 10896122
[TBL] [Abstract][Full Text] [Related]
25. Ligand-based chemoinformatic discovery of a novel small molecule inhibitor targeting CDC25 dual specificity phosphatases and displaying in vitro efficacy against melanoma cells.
Capasso A; Cerchia C; Di Giovanni C; Granato G; Albano F; Romano S; De Vendittis E; Ruocco MR; Lavecchia A
Oncotarget; 2015 Nov; 6(37):40202-22. PubMed ID: 26474275
[TBL] [Abstract][Full Text] [Related]
26. Halenaquinone and xestoquinone derivatives, inhibitors of Cdc25B phosphatase from a Xestospongia sp.
Cao S; Foster C; Brisson M; Lazo JS; Kingston DG
Bioorg Med Chem; 2005 Feb; 13(4):999-1003. PubMed ID: 15670907
[TBL] [Abstract][Full Text] [Related]
27. Pharmacophore-guided discovery of CDC25 inhibitors causing cell cycle arrest and tumor regression.
Kabakci Z; Käppeli S; Cantù C; Jensen LD; König C; Toggweiler J; Gentili C; Ribaudo G; Zagotto G; Basler K; Pinna LA; Cozza G; Ferrari S
Sci Rep; 2019 Feb; 9(1):1335. PubMed ID: 30718768
[TBL] [Abstract][Full Text] [Related]
28. Naphthoquinone analogs as inactivators of cdc25 phosphatase.
Ham SW; Park J; Lee SJ; Kim W; Kang K; Choi KH
Bioorg Med Chem Lett; 1998 Sep; 8(18):2507-10. PubMed ID: 9873570
[TBL] [Abstract][Full Text] [Related]
29. Design and synthesis of novel bis-thiazolone derivatives as micromolar CDC25 phosphatase inhibitors: effect of dimerisation on phosphatase inhibition.
Sarkis M; Tran DN; Kolb S; Miteva MA; Villoutreix BO; Garbay C; Braud E
Bioorg Med Chem Lett; 2012 Dec; 22(24):7345-50. PubMed ID: 23141909
[TBL] [Abstract][Full Text] [Related]
30. H32, a non-quinone sulfone analog of vitamin K3, inhibits human hepatoma cell growth by inhibiting Cdc25 and activating ERK.
Kar S; Wang M; Ham SW; Carr BI
Cancer Biol Ther; 2006 Oct; 5(10):1340-7. PubMed ID: 16969075
[TBL] [Abstract][Full Text] [Related]
31. Arrest at the G2/M transition of the cell cycle by protein-tyrosine phosphatase inhibition: studies on a neuronal and a glial cell line.
Faure R; Vincent M; Dufour M; Shaver A; Posner BI
J Cell Biochem; 1995 Nov; 59(3):389-401. PubMed ID: 8567756
[TBL] [Abstract][Full Text] [Related]
32. 2-(Thienothiazolylimino)-1,3-thiazolidin-4-ones inhibit cell division cycle 25 A phosphatase.
Huber-Villaume S; Revelant G; Sibille E; Philippot S; Morabito A; Dunand S; Chaimbault P; Bagrel D; Kirsch G; Hesse S; Schohn H
Bioorg Med Chem; 2016 Jul; 24(13):2920-2928. PubMed ID: 27178385
[TBL] [Abstract][Full Text] [Related]
33. Discovery and characterization of a novel inhibitor of CDC25B, LGH00045.
Feng X; Wang LN; Zhou YY; Yu HP; Shen Q; Zang Y; Zhou YB; Li JY; Zhang HX; Li J
Acta Pharmacol Sin; 2008 Oct; 29(10):1268-74. PubMed ID: 18817634
[TBL] [Abstract][Full Text] [Related]
34. Anthraquinones, Cdc25B phosphatase inhibitors, isolated from the roots of Polygonum multiflorum Thunb.
Choi SG; Kim J; Sung ND; Son KH; Cheon HG; Kim KR; Kwon BM
Nat Prod Res; 2007 May; 21(6):487-93. PubMed ID: 17497420
[TBL] [Abstract][Full Text] [Related]
35. CDC25A and B dual-specificity phosphatase inhibitors: potential agents for cancer therapy.
Lavecchia A; Di Giovanni C; Novellino E
Curr Med Chem; 2009; 16(15):1831-49. PubMed ID: 19442149
[TBL] [Abstract][Full Text] [Related]
36. A novel coumarin-quinone derivative SV37 inhibits CDC25 phosphatases, impairs proliferation, and induces cell death.
Bana E; Sibille E; Valente S; Cerella C; Chaimbault P; Kirsch G; Dicato M; Diederich M; Bagrel D
Mol Carcinog; 2015 Mar; 54(3):229-41. PubMed ID: 24155226
[TBL] [Abstract][Full Text] [Related]
37. Inhibition of human tumor cell growth in vivo by an orally bioavailable inhibitor of CDC25 phosphatases.
Brezak MC; Quaranta M; Contour-Galcera MO; Lavergne O; Mondesert O; Auvray P; Kasprzyk PG; Prevost GP; Ducommun B
Mol Cancer Ther; 2005 Sep; 4(9):1378-87. PubMed ID: 16170030
[TBL] [Abstract][Full Text] [Related]
38. Discovery and characterization of novel imidazopyridine derivative CHEQ-2 as a potent CDC25 inhibitor and promising anticancer drug candidate.
Song Y; Lin X; Kang D; Li X; Zhan P; Liu X; Zhang Q
Eur J Med Chem; 2014 Jul; 82():293-307. PubMed ID: 24922544
[TBL] [Abstract][Full Text] [Related]
39. Cdc25B phosphatase inhibitors in cancer therapy: latest developments, trends and medicinal chemistry perspective.
Lavecchia A; Coluccia A; Di Giovanni C; Novellino E
Anticancer Agents Med Chem; 2008 Dec; 8(8):843-56. PubMed ID: 19075567
[TBL] [Abstract][Full Text] [Related]
40. Synthesis and biological evaluation of 3-aminoisoquinolin-1(2H)-one based inhibitors of the dual-specificity phosphatase Cdc25B.
George Rosenker KM; Paquette WD; Johnston PA; Sharlow ER; Vogt A; Bakan A; Lazo JS; Wipf P
Bioorg Med Chem; 2015 Jun; 23(12):2810-8. PubMed ID: 25703307
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
